Partners HealthCare

Despite years of experience of returning genetic test results, clinicians and researchers are still faced with many questions, such as what to do about VUS and secondary findings.

The FDA, journals, and even payors are encouraging labs to deposit variant data in public databases, but collaboration is needed to resolve interpretation discrepancies.

Integrated healthcare systems are corralling their resources and capabilities in applying for a shot to enroll volunteers to the national project.

Vanderbilt University, the University of Colorado at Denver, Partners HealthCare, and the Montreal Heart Institute will use Illumina technology to analyze their biobank samples.

Sunquest now offers GeneInsight as part of its laboratory information management system solution and is working with Partners to develop new capabilities for the clinical genomics tool.

The lab has also switched its gene panels from the Illumina HiSeq to the MiSeq platform.

NEW YORK (GenomeWeb) – Sunquest Information Systems and Partners Healthcare announced on Thursday a strategic alliance to provide genetic testing workflow capabilities to clinical geneticists and pathologists.

NEW YORK (GenomeWeb News) – The National Heart, Lung, and Blood Institute is providing $12 million to Partners HealthCare and its founding hospitals to create the Boston Biomedical Innovation Center to accelerate the translation of scientific discoveries into commercial products, Partners said on

After two years of development, Partners HealthCare launched a clinical whole-genome sequencing test for rare genetic disorders this summer and plans to offer a lower-priced clinical exome test by the end of the year.

Partners HealthCare has launched clinical whole-genome sequencing and interpretation services for patients with suspected genetic conditions as a collaboration between Partners Laboratory for Molecular Medicine, Mass General Hospital and

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.